Helping Togolese women plan and space their pregnancies since 1989.
- Postpartum intrauterine device (PPIUD) services are now available at 50 health care facilities in Togo, with providers ready to meet the needs of postpartum women in surrounding areas.
- More than 200 providers have been trained to provide accurate and appropriate information on postpartum family planning, including PPIUDs, to pregnant women and can refer them to a health care facility where these services are provided if they are not available at their own site.
- More than 2,510 PPIUDs have been inserted at Jhpiego-supported health care facilities for postpartum women seeking to delay their next pregnancy.
- Jhpiego Togo developed an innovative training approach to scale up services for an innovative injectable contraceptive method (depot-medroxyprogesterone acetate, also known as Sayana® Press); this approach has been used to build the capacity of 303 health care providers to provide this service. Jhpiego Togo also worked with Togo’s Ministry of Health to develop self-injection guidelines.
Our Work in Togo
With funding from Family Planning 2020’s Rapid Response Mechanism, Jhpiego is supporting the Ministry of Health’s Department of Family Health to introduce, learn from and scale up subcutaneous depot-medroxyprogesterone acetate (DMPA-SC) in two health districts. DMPA-SC is an innovative injectable contraceptive—also known as Sayana® Press—that can dramatically expand access and choice for women who want to use contraception. Under this project, Jhpiego and the Department of Family Health are building the capacity of facility-based health care providers and community-based health workers to provide DMPA-SC and introduce two approaches for the provision of DMPA-SC in districts where intramuscular DMPA is not available. In Kloto, the project is introducing community-based distribution of DMPA-SC by community health workers; in Gulf, the focus is on facility-based providers supporting clients to self-inject DMPA-SC. The project will document learning from these two approaches to support the Department of Family Health to rapidly scale up DMPA-SC across Togo.
Funded by the Bill & Melinda Gates Foundation, this program promotes access to family planning choices in West African countries by supporting the introduction and scale-up of subcutaneous depot-medroxyprogesterone acetate (DMPA-SC). DMPA-SC is an innovative injectable contraceptive—also known as Sayana® Press—that can dramatically expand access and choice for women. Jhpiego is enhancing ongoing efforts of the Access Collaborative by strengthening health systems to accelerate introduction and scale-up of DMPA-SC in several West African countries, including Togo.